Drugs / IZORLISIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03767335 | Nov 2018 → Feb 2024 | breast cancer | Menarini Group | Completed | No outcome recorded |
| Phase 1 | NCT01222546 | Aug 2010 → Nov 2012 | cancer | Chugai Pharma Europe Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04495621 | Jul 2020 → Jan 2024 | colorectal cancer | Menarini Group | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05810870 | May 2023 → Apr 2026 overdue | breast cancer | MedSIR | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IZORLISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684984 ↗ |
| Known as | CH5132799 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01222546 ↗ |
| Known as | CH5132799-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684984 ↗ |
| Known as | MEN1611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767335 ↗ |
| Known as | PA-799 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1684984 ↗ |
| Action | Inhibit | “MEN1611 is an investigational drug which blocks a protein called PI3K” NCT03767335 ↗ |
| Modality | Small molecule | — CHEMBL1684984 ↗ |
| Route | Oral | “administered orally” NCT01222546 ↗ |
| Target | PIK3CA | “PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.” NCT05810870 ↗ |